Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars
06. Dezember 2022 07:00 ET
|
Jeito Capital
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Ce nouveau tour de table permettra d’accélérer le développement clinique et...
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
15. September 2021 07:00 ET
|
Pulmocide
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA Pulmocide raised $92 million in Series C funds...
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
15. September 2021 02:00 ET
|
Pulmocide
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA Pulmocide raised $92 million in Series C funds...
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
27. Mai 2021 07:00 ET
|
Pulmocide
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company...
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide
27. Mai 2021 02:00 ET
|
Jeito Capital
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma...
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
27. Mai 2021 02:00 ET
|
Pulmocide
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company...
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections
11. März 2021 08:00 ET
|
Pulmocide
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections Case studies...
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence
13. August 2019 07:00 ET
|
Pulmocide
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence C.auris is often multi-drug...